{"disease":{"id":"partial-onset-seizures","name":"partial-onset seizures","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lyrica","indication_name":"Adjunctive therapy for partial-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"gabapentin","indication_name":"Partial Onset Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"gabapentin","company_name":"Generic (originally Parke-Davis/Pfizer)","drug_phase":"marketed","molecular_target":"Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor","drug_class":"Gabapentinoid (anticonvulsant/neuropathic pain agent)","quality_score":10,"revenue":null,"mechanism":"Binds the alpha-2-delta subunit of voltage-gated calcium channels, modulating neurotransmitter release to treat neuropathic pain and seizures."},{"drug_id":"lyrica","indication_name":"Adjunctive therapy for partial-onset seizures in patients 1 month of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyrica","generic_name":"Pregabalin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)","drug_class":"Anticonvulsant, analgesic","quality_score":10,"revenue":null,"mechanism":"Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels in CNS."},{"drug_id":"eslicarbazepine","indication_name":"partial-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eslicarbazepine Acetate","generic_name":"ESLICARBAZEPINE","company_name":"Sumitomo Pharma Am","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Eslicarbazepine acetate works by stabilizing sodium channels in the brain, reducing the abnormal electrical activity that causes seizures."},{"drug_id":"bat","indication_name":"Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01618695","title":"A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":940,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT01832038","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"UCB Pharma SA","has_results":true},{"nct_id":"NCT00448539","title":"Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":286,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT02477839","title":"Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"UCB BIOSCIENCES, Inc.","has_results":true},{"nct_id":"NCT03836924","title":"A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Eisai Pharmaceuticals India Pvt. Ltd","has_results":false},{"nct_id":"NCT04252846","title":"A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Eisai Limited","has_results":false},{"nct_id":"NCT02849626","title":"Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT02072824","title":"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT04230044","title":"A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT06960811","title":"Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT06657378","title":"A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures","phase":"","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT04015141","title":"A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT03201900","title":"Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT01051193","title":"Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Nobelpharma","has_results":false},{"nct_id":"NCT03288129","title":"Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT04095182","title":"Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Whanin Pharmaceutical Company","has_results":false},{"nct_id":"NCT01871233","title":"An Extended Access Program for Perampanel","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT02307578","title":"An Extended Access Program (EAP) for Perampanel","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Eisai Inc.","has_results":false}],"total":18},"guidelines":[{"drug_id":"levetiracetam","guideline_body":"FDA label","recommendation":"Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}